Open house Arzneimittelrabattverträge Vildagliptin, ATC A10BH02
Originaltitel der Bekanntmachung
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Vildagliptin, ATC A10BH02
Opportunity Score
Warum diese Bewertung?
Chance
55 / 100
Komplexität
20 / 100
Risikofaktoren
The open-house agreements automatically expire if a competitive rebate contract (national or regional) for Vildagliptin...
The agreements are non-exclusive and do not ensure any sales volume; they only provide a rebate framework. Actual sales...
Tiefe Portfolioanalyse
Verwendet:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Überblick
Strong opportunityWichtige Fakten
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Nov 2026
- Non-exclusive rebate agreements for Vildagliptin (ATC A10BH02) for AOK Bayern.
- All eligible pharmaceutical companies can participate; no selection process.
Vollständige Zusammenfassung anzeigen
AOK Bayern is implementing a non-exclusive open-house model for pharmaceutical rebate agreements for the active ingredient Vildagliptin (ATC A10BH02) under §130a Abs. 8 SGB V. All qualified pharmaceutical companies can enter into identical, non-negotiable rebate agreements. The earliest contract start is 01.12.2024, all agreements end 30.11.2026. Joining is possible any time until 05.10.2026. The procedure is not subject to public procurement law; it is a voluntary open-house model with no selection of contractors. Only pharmaceutical companies are eligible. Submission requires a signed self-declaration of reliability and the signed contract with annex. Documents can be submitted in paper (2 copies) or electronically with qualified electronic signature. The buyer is AOK Bayern. No estimated value is provided. Award criteria are not applicable as all eligible participants are accepted.
Risiken
The open-house agreements automatically expire if a competitive rebate contract (national or regional) for Vildagliptin...
The agreements are non-exclusive and do not ensure any sales volume; they only provide a rebate framework. Actual sales...
Analyse kann unvollständig sein
Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.
Wichtige Anforderungen
Technical
- Signed contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel' required.
Eligibility
- Only pharmaceutical companies are eligible (potential contractors).
Administrative
- Signed self-declaration of reliability must be submitted.
Auftraggeber
Ort
München, DEU
Website
Auftraggeberprofil
Kennung
DE811695320
Tätigkeit
Health
Lose (1)
LOT-0001
Open house Arzneimittelrabattverträge Vildagliptin, ATC A10BH02
Open-house model for non-exclusive rebate agreements for Vildagliptin (ATC A10BH02) to be concluded with any interested pharmaceutical company that meets the eligibility criteria. Agreements are identical and non-negotiable. Contract period: 01.12.2024 to 30.11.2026.
Ort
Dauer
Kategorie
Frist
Zuschlagsdetails
Siehe kurze Beschreibung
Hinweis zum Wert
Originale TED-Daten anzeigen
Originale TED-Beschreibung
Siehe kurze Beschreibung
Vergabedetails
- Veröffentlichungsdatum
- 16 Oct 2024
- Sprachen
- German
Referenzmetadaten
- Rechtsgrundlage
- 32014L0024
Referenz-IDs
- Ausschreibungs-ID
- 628246-2024
Dokumente (2)
Ähnliche Ausschreibungen
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Warum diese Bewertung?
Chance
55 / 100
Komplexität
20 / 100
Risikofaktoren
The open-house agreements automatically expire if a competitive rebate contract (national or regional) for Vildagliptin...
The agreements are non-exclusive and do not ensure any sales volume; they only provide a rebate framework. Actual sales...
Tiefe Portfolioanalyse
Verwendet:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications